Tvardi Therapeutics (TVRD) Competitors

Tvardi Therapeutics logo
$1.01 -0.09 (-8.18%)
Closing price 04:00 PM Eastern
Extended Trading
$1.05 +0.04 (+3.96%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TVRD vs. ELOX, DWTX, ATHE, LONA, and GRCE

Should you buy Tvardi Therapeutics stock or one of its competitors? Tvardi Therapeutics's main competitors and comparable companies include Eloxx Pharmaceuticals (ELOX), Dogwood Therapeutics (DWTX), Alterity Therapeutics (ATHE), Athira Pharma (LONA), and Grace Therapeutics (GRCE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Tvardi Therapeutics compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Eloxx Pharmaceuticals presently has a consensus target price of $37.33, indicating a potential upside of 192.81%. Tvardi Therapeutics has a consensus target price of $9.40, indicating a potential upside of 754.55%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tvardi Therapeutics is more favorable than Eloxx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eloxx Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
2.86
Tvardi Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

Eloxx Pharmaceuticals has higher earnings, but lower revenue than Tvardi Therapeutics. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eloxx PharmaceuticalsN/AN/A-$5.99M-$1.54N/A
Tvardi Therapeutics$7.14M2.06-$18.21M-$2.68N/A

In the previous week, Eloxx Pharmaceuticals had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 4 mentions for Eloxx Pharmaceuticals and 3 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 1.61 beat Eloxx Pharmaceuticals' score of 0.72 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eloxx Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tvardi Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Eloxx Pharmaceuticals' return on equity of 0.00% beat Tvardi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eloxx PharmaceuticalsN/A N/A N/A
Tvardi Therapeutics N/A -145.40%-91.11%

Eloxx Pharmaceuticals has a beta of -1918.69, indicating that its share price is 191,969% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

2.9% of Eloxx Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are owned by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Eloxx Pharmaceuticals and Tvardi Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Dogwood Therapeutics?

Dogwood Therapeutics (NASDAQ:DWTX) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 4 mentions for Dogwood Therapeutics and 3 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 1.61 beat Dogwood Therapeutics' score of 0.80 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dogwood Therapeutics
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tvardi Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Dogwood Therapeutics' return on equity of -34.97% beat Tvardi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Dogwood TherapeuticsN/A -34.97% -29.50%
Tvardi Therapeutics N/A -145.40%-91.11%

Dogwood Therapeutics presently has a consensus target price of $12.00, suggesting a potential upside of 1,032.08%. Tvardi Therapeutics has a consensus target price of $9.40, suggesting a potential upside of 754.55%. Given Dogwood Therapeutics' higher probable upside, analysts clearly believe Dogwood Therapeutics is more favorable than Tvardi Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dogwood Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Tvardi Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

Dogwood Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market.

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Tvardi Therapeutics has higher revenue and earnings than Dogwood Therapeutics. Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dogwood TherapeuticsN/AN/A-$34.26M-$0.89N/A
Tvardi Therapeutics$7.14M2.06-$18.21M-$2.68N/A

Summary

Tvardi Therapeutics beats Dogwood Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends, earnings and media sentiment.

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Alterity Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 410.20%. Tvardi Therapeutics has a consensus price target of $9.40, suggesting a potential upside of 754.55%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Alterity Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alterity Therapeutics
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Tvardi Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

Alterity Therapeutics has higher earnings, but lower revenue than Tvardi Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alterity TherapeuticsN/AN/A-$15.88MN/AN/A
Tvardi Therapeutics$7.14M2.06-$18.21M-$2.68N/A

In the previous week, Tvardi Therapeutics had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 3 mentions for Tvardi Therapeutics and 2 mentions for Alterity Therapeutics. Tvardi Therapeutics' average media sentiment score of 1.61 beat Alterity Therapeutics' score of 0.89 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alterity Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tvardi Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Alterity Therapeutics' return on equity of 0.00% beat Tvardi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alterity TherapeuticsN/A N/A N/A
Tvardi Therapeutics N/A -145.40%-91.11%

Alterity Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Summary

Tvardi Therapeutics beats Alterity Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Athira Pharma?

Tvardi Therapeutics (NASDAQ:TVRD) and Athira Pharma (NASDAQ:LONA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Tvardi Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

Tvardi Therapeutics has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tvardi Therapeutics$7.14M2.06-$18.21M-$2.68N/A
Athira PharmaN/AN/A-$105.61M-$4.21N/A

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by insiders. Comparatively, 25.7% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Tvardi Therapeutics and Tvardi Therapeutics both had 3 articles in the media. Athira Pharma's average media sentiment score of 1.82 beat Tvardi Therapeutics' score of 1.61 indicating that Athira Pharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Tvardi Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Athira Pharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Tvardi Therapeutics' return on equity of -145.40% beat Athira Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Tvardi TherapeuticsN/A -145.40% -91.11%
Athira Pharma N/A -411.58%-225.73%

Tvardi Therapeutics presently has a consensus target price of $9.40, suggesting a potential upside of 754.55%. Athira Pharma has a consensus target price of $17.33, suggesting a potential upside of 436.64%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Tvardi Therapeutics is more favorable than Athira Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tvardi Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88
Athira Pharma
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50

Summary

Tvardi Therapeutics beats Athira Pharma on 9 of the 13 factors compared between the two stocks.

How does Tvardi Therapeutics compare to Grace Therapeutics?

Grace Therapeutics (NASDAQ:GRCE) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Grace Therapeutics has a beta of 0.43, indicating that its stock price is 57% less volatile than the broader market. Comparatively, Tvardi Therapeutics has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

In the previous week, Grace Therapeutics had 3 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 6 mentions for Grace Therapeutics and 3 mentions for Tvardi Therapeutics. Tvardi Therapeutics' average media sentiment score of 1.61 beat Grace Therapeutics' score of 0.81 indicating that Tvardi Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Grace Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tvardi Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Grace Therapeutics currently has a consensus price target of $6.00, suggesting a potential upside of 242.86%. Tvardi Therapeutics has a consensus price target of $9.40, suggesting a potential upside of 754.55%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than Grace Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Grace Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Tvardi Therapeutics
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.88

6.1% of Grace Therapeutics shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 10.8% of Grace Therapeutics shares are owned by company insiders. Comparatively, 7.4% of Tvardi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Grace Therapeutics has higher earnings, but lower revenue than Tvardi Therapeutics. Grace Therapeutics is trading at a lower price-to-earnings ratio than Tvardi Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Grace TherapeuticsN/AN/A-$7.79M-$1.23N/A
Tvardi Therapeutics$7.14M2.06-$18.21M-$2.68N/A

Grace Therapeutics' return on equity of -36.29% beat Tvardi Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Grace TherapeuticsN/A -36.29% -34.69%
Tvardi Therapeutics N/A -145.40%-91.11%

Summary

Grace Therapeutics and Tvardi Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Tvardi Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TVRD vs. The Competition

MetricTvardi TherapeuticsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$14.70M$13.61B$7.74B$11.66B
Dividend YieldN/A2.58%2.46%4.42%
P/E RatioN/A29.4034.1729.86
Price / Sales1.897.028.485.62
Price / CashN/A15.7421.9322.50
Price / Book0.875.114.373.66
Net Income-$18.21M$2.88B$3.52B$392.27M
7 Day Performance-28.37%-4.10%-5.47%-4.73%
1 Month PerformanceN/A-5.08%-4.57%-7.14%
1 Year Performance-74.94%-7.47%-1.79%-7.51%

Tvardi Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TVRD
Tvardi Therapeutics
3.8039 of 5 stars
$1.01
-8.2%
$9.40
+830.7%
-72.7%$14.70M$7.14MN/A12
ELOX
Eloxx Pharmaceuticals
3.482 of 5 stars
$12.44
flat
$37.33
+200.1%
N/A$50.26M$6.36MN/A7
DWTX
Dogwood Therapeutics
2.7426 of 5 stars
$1.28
flat
$12.00
+837.5%
-81.0%$48.93MN/AN/A8
ATHE
Alterity Therapeutics
3.7195 of 5 stars
$2.43
flat
$10.00
+311.5%
-49.0%$44.05MN/AN/A11
LONA
Athira Pharma
3.5131 of 5 stars
$4.41
-0.2%
$17.33
+293.0%
N/A$41.47MN/AN/A19

Related Companies and Tools


This page (NASDAQ:TVRD) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners